Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Initiating biologics as the first systemic therapy was associated with better clinical outcomes compared with standard stepwise approaches. These results support reconsideration of existing pathways to allow earlier use of biologics.
Authors
- Zenas Z N Yiu (ORCID: https://orcid.org/0000-0002-1831-074X)
- Olivia Hughes (ORCID: https://orcid.org/0000-0001-9587-9430)
- Oras Alabas (ORCID: https://orcid.org/0000-0003-2002-0781)
- Mark Lunt (ORCID: https://orcid.org/0000-0002-2391-5575)
- Duc Binh Phan (ORCID: https://orcid.org/0000-0002-8916-9093)
- Ruth Warren (ORCID: https://orcid.org/0000-0002-1320-6433)
- G Rogers (ORCID: https://orcid.org/0000-0001-9339-7374)
- Christopher E. M. Griffiths
- Catherine H Smith
- Philip Laws
- Brian Kirby
Institutions
- University of Leeds (GB)
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Manchester Academic Health Science Centre (GB)
- Thomas Foundation (AU)
- St. Vincent's University Hospital (IE)
- Arthritis UK (GB)
- King's College Hospital (GB)
- NIHR Manchester Biomedical Research Centre (GB)
- Cardiff University (GB)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1093/bjd/ljag098
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00